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Abstract  
The 6th National Audit Project on perioperative anaphylaxis collected and reviewed 266 reports of 
grade 3-5 anaphylaxis over one year from all National Health Service hospitals. This paper describes 
management, outcomes and subspecialty data: the full report is at 
http://www.nationalauditprojects.org.uk/NAP6Report#pt . Quality of management was assessed 
against published guidelines on management of anaphylaxis and cardiac arrest. All patients were 
resuscitated by anaesthetists of appropriate seniority. A management guideline was immediately 
available in 86% of cases. Immediate management was judged ‘good’ in 46% and ‘poor’ in 15% of 
cases. Recognition of and treatment of anaphylaxis were judged prompt in 97.3% and 83.4% of 
cases, respectively. Adrenaline was administered IV in 76% of cases, IM in 14% and both in 6%. No 
adrenaline was administered in 11%. The majority received other vasopressors (metaraminol, 
phenylephrine) before adrenaline. An IV infusion of adrenaline or noradrenaline was administered in 
30.7% and 18.9% of cases, respectively. Two patients received vasopressin and one glucagon. 
Steroids and antihistamines were generally administered early. Careful examination of the role of 
antihistamines found no evidence of harm and could not exclude evidence of benefit. Sugammadex 
was given to treat anaphylaxis in 7.1% of cases. IV fluid administration was inadequate in 19% of 
cases. Cardiac arrests (15% of cases) were promptly treated; mean duration of cardiac compressions 
was 14 minutes, but cardiac compressions were performed in only 50% of patients with 
unrecordable blood pressure. The surgical procedure was postponed or abandoned in two thirds, 
and urgent surgery was delayed in 10% of all cases. More than half of patients required admission to 
critical care: 70% for level 3 care and most of these patients required catecholamine infusions after 
admission. Adverse sequelae were reported in a third of cases, including new anxiety, change in 
mood, impaired memory, impaired coordination, impaired mobility, symptoms of post-traumatic 
stress disorder, myocardial damage, heart failure and new renal impairment. Ten deaths (3.8%) 
were attributable to anaphylaxis, a per case mortality rate of 1 in 26.6 cases.  Six per cent of 
survivors underwent uneventful surgery between the index event and the patient being seen in 
clinic.  
 
 
Keywords: anaphylaxis; anaesthesia; outcomes; allergy; National Audit Project 
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Key findings 
 All patients were resuscitated by an anaesthetist of appropriate grade and recognition of a 
critical event was prompt.  
 Recognition of a critical event and of anaphylaxis was generally very prompt. 
 There was delay in starting anaphylaxis-specific treatment in 25% cases, illustrating the potential 
difficulties inherent in recognition of perioperative anaphylaxis. 
 Airway management was generally uncomplicated and without difficulty.  A single front of neck 
airway was judged the only case of airway morbidity associated with anaphylaxis. 
 When cardiac compressions were indicated there was delay starting them in more than half of 
cases.   
 Vasopressin and glucagon were very rarely used. 
 Sugammadex was administered in seven rocuronium-induced cases and no further 
pharmacological treatment was needed in four. 
 Fluid administration was frequently judged to be insufficient and was inappropriate in 19%. 
 The review panel judged management to be ‘good’ or ‘good-and-poor-elements’ in 85% of 
cases.  
 Careful examination of the role of antihistamines found no evidence of harm and could not 
exclude evidence of benefit. 
 More than half of patients required admission to critical care: 70% for level 3 care and most of 
these patients required catecholamine infusions after admission.  
 Six per cent of survivors underwent surgery between the index event and the patient being seen 
in clinic. This was uneventful in every case. 
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Successful management of perioperative anaphylaxis is critically dependent on early recognition and 
prompt initiation of specific treatment. Recognition that a critical event occurring during anaesthesia 
is likely to be anaphylaxis may not be straightforward and the differential diagnosis is wide. The 
onset may be immediate or delayed and the patient’s medical history rarely provides any clues. 
Rash, the classical sign of an allergic reaction, is present in approximately half of cases but may be 
not visible under surgical drapes or delayed, especially in more severe cases. Hypotension is usually 
the first sign of perioperative anaphylaxis.
1
 A modest fall in blood pressure is a frequent 
accompaniment of general anaesthesia
2
 as well as during neuraxial anaesthesia, and vasopressor 
drugs are often required during routine anaesthesia. It is only when the blood pressure does not 
respond that less common causes of hypotension are sought, including ischaemic cardiac event, 
cardiac arrhythmia, embolus, pneumothorax, covert haemorrhage and anaphylaxis. 
 
Similarly, bronchospasm, a not uncommon accompaniment of general anaesthesia, especially in 
asthmatic patients is the first clinical feature in 18% of cases of perioperative anaphylaxis
1
 and 
anaphylaxis may not be the first differential diagnosis. 
 
 It is generally agreed that adrenaline is the mainstay of management and is recommended in all 
published guidelines.
3–10
 Having both alpha and beta agonist properties, adrenaline has compelling 
theoretical advantages in the treatment of anaphylaxis by ameliorating many of the 
pathophysiological processes (Figure 1) 
 
(Figure 1 near here) 
 
The beneficial actions of adrenaline include venoconstriction which increases venous return, 
reduced capillary permeability, increased cardiac contractility and cardiac output, bronchodilatation 
and inhibition of mast cell and basophil mediator release. These benefits exceed the disadvantages 
of vasodilatation in skeletal muscle and the potential risk of cardiac arrhythmias. Early 
administration of adrenaline is associated with improved outcomes in out-of-hospital anaphylaxis.
11
 
 
McLean-Tooke
12
 concluded that adrenaline is not contra-indicated in patients with coronary artery 
disease as continuing anaphylaxis likely further reduces coronary artery perfusion. However, 
excessive dose or over-rapid IV administration can cause arrhythmias. Intravenous adrenaline is 
more likely than intramuscular (IM) to result in cardiac complications in treatment of out-of-hospital 
anaphylaxis in elderly patients
13
 but there is no published information regarding the perioperative 
setting. The IV and IM routes are both recommended for the treatment of perioperative 
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anaphylaxis; the IV route restricted to patients with continuous vital-signs monitoring, including 
continuous ECG.
9
 The Association of Anaesthetists of Great Britain and Ireland (AAGBI) guidelines 
recommend an initial IV dose of 50mcg, repeated as necessary 
3
. The Australian and New Zealand 
Anaesthetic Allergy Group (ANZAAG) guidance for Grade 3 reactions recommend an initial IV dose of 
100mcg followed, if necessary, by 100-200mcg every 1-2 minutes and a continuous infusion after 3 
IV boluses.
14
  
 
Metaraminol is a second-line treatment in AAGBI guidelines 
3
  but widely available in anaesthesia 
settings. Several case reports describe survival after use of IV vasopressin 2-15 units (antidiuretic 
hormone)  in the management of intractable perioperative anaphylaxis,
15–18
and this drug is included 
in the ANZAAG guidelines .
14
 The benefit of adrenaline is likely reduced in the presence of beta 
blockade. There are single case reports of glucagon use in beta-blocked patients leading to rapid 
resolution of hypotension.
19
 
20
 European
21
 and ANZAAG
14
 guidelines recommend 1-2mg every 5 
minutes until response, but it is not known how commonly glucagon and vasopressin are used to 
treat perioperative anaphylaxis in UK practice. 
 
There are no published randomized controlled trials (RCTs) investigating the efficacy of 
corticosteroids in the acute management of anaphylaxis. The rationale for their administration in 
anaphylaxis appears to be down-regulation of the late-phase response by altering gene expression 
and is an extrapolation of their effectiveness in the long-term management of allergic asthma 
22
. 
Hydrocortisone is recommended in published guidelines. Dexamethasone 7.5mg has an equivalent 
glucocorticoid effect to hydrocortisone 200mg (https://bnf.nice.org.uk/treatment-
summary/glucocorticoid-therapy.html)  
 
The use of antihistamines in relatively minor out-of-hospital allergic reactions benefits urticaria and 
pruritus. A Cochrane review of H1 anti-histamines for anaphylaxis was unable to make any 
recommendations, as a result of lack of evidence.
23
 This statement, together with side-effects of 
promethazine, has resulted in some expert groups recommending anti-histamines should not be 
administered.
14
 We aimed to establish whether administration of chlorphenamine, the most 
commonly used antihistamine, influenced outcome. 
 
Several case reports may be considered supportive of  administration of sugammadex during 
rocuronium-induced anaphylaxis.
24 25
 
26
 The hypothesis that encapsulating the antigen may halt the 
clinical features of anaphylaxis is unproven, despite in vitro and clinical studies. 
27
 Platt et al
28
 
reported sugammadex administration during immediate management of suspected rocuronium-
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induced anaphylaxis, in 13 cases, of which five were not rocuronium-induced. Clinical features 
improved in six patients, including three without rocuronium-induced anaphylaxis: raising the 
possibility that sugammadex may exert a vasopressor effect via a mechanism other than 
encapsulating the antigen. We sought to determine to what extent sugammadex has been 
incorporated in current management of perioperative anaphylaxis. 
 
Anaphylaxis is associated with an acute fall in actual and effective circulating blood volume as a 
result of vasodilatation, increased vascular permeability and fluid sequestration, causing reduced 
venous return and cardiac output (Figure 1) and there is consensus for rapid IV infusion of crystalloid 
fluids. Recent guidelines emphasise the need to give rapid, repeated IV fluid challenges whilst 
monitoring the response: ANZAAG guidelines
14
 recommend giving repeated boluses of 20ml/kg. 
There is a paucity of information concerning IV fluid management in ‘real life’ management of 
perioperative anaphylaxis but we support these recommendations. 
 
Little is known about the outcomes of perioperative anaphylaxis and we sought to establish the 
influence of patient demographics, concomitant medication, co-morbidities and the quality of 
resuscitation. Lastly, we aimed to characterise perioperative anaphylaxis in two important groups: 
obstetric patients and children. 
 
Methods 
Methods are discussed in detail in an accompanying paper.
29
 At panel review the quality of 
immediate management was assessed and classified including factors such as timeliness, accuracy 
and completeness. In doing this we also referred to current guidelines of the AAGBI and 
Resuscitation Council of the United Kingdom (RCUK) on management of perioperative anaphylaxis
30
 
and cardiac arrest
31
where relevant. The overall initial management was graded as ‘good’, ‘good and 
poor’ or ‘poor’. 
 
Although administration of adrenaline is the accepted standard for the immediate management of 
perioperative anaphylaxis, the review panel recognised that anaphylaxis is an uncommon cause of 
hypotension or bronchospasm during anaesthesia. It is therefore reasonable for anaesthetists to 
start treatment with vasopressors and bronchodilators such as metaraminol, ephedrine and 
salbutamol before instituting anaphylaxis-specific treatment, unless anaphylaxis was clinically-
obvious from the outset. Results here are based on a dataset of the 266 reviewed cases of confirmed 
anaphylaxis. For some analyses a smaller dataset is used. The quality of delivered care is based on a 
full panel review of 184 cases.
29
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Results 
Resuscitation was performed by an anaesthetist of appropriate grade in all cases. The review panel 
considered that overall management was good in 46% cases; good and poor in 39%, and poor in 15% 
(Figure 2). 
 
(Figure 2 near here) 
 
Recognition of a critical incident and suspicion of anaphylaxis was within five minutes in 60% and 
49% of cases, respectively.  By 10 minutes, the corresponding figures were 78% and 74%. 
Recognition of anaphylaxis and treatment were judged prompt in 97.3% and 83.4% of cases 
respectively (Figure 3). 
 
(Figure 3 near here) 
 
Specific treatment for anaphylaxis following the first clinical feature was started in <5 minutes in 
64% of cases and <10 minutes in 83%. (Figure 4). Reported reasons for delay included confounding 
differential diagnoses such as pulmonary embolism, tension pneumothorax, gas embolism during 
abdominal endoscopy, primary cardiac events, surgical haemorrhage and neuraxial blockade 
associated hypotension. 
 
(Figure 4 near here) 
 
Pharmacological treatment was judged prompt and comprehensive in 83.9% and 98.8% of cases 
respectively. The vasoactive drugs administered are shown in Figure 5. Adrenaline was administered 
in 82.3% of cases; as IV boluses in 75.9% and was more likely to be given as severity increased. The 
median total dose was 0.2mg, 0.5mg and 4mg in severity-grades 3, 4 and 5 respectively. There was 
wide variation in the number of IV doses, ranging from one to thirty (median three doses). 
Recognition of anaphylaxis was delayed in approximately one third of cases. The IM route was used 
in 14.1% of cases. Sixteen patients (6%) received both IV and IM adrenaline. 
 
(Figure 5 near here) 
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An IV infusion of adrenaline was used in 30.7%, preceded by bolus doses in all except a single case. 
Adrenaline was judged not to have been given when indicated in 19.4% of cases; either not 
administered (11%) or given late (8.4%). 
 
Metaraminol boluses were administered in 68.7% of patients of whom 73.6% also received 
adrenaline. Phenylephrine was administered by IV bolus in 7.8% of cases and an infusion in 3.5%. 
Most cases were obstetric. An IV infusion of noradrenaline was administered in 18.9% of cases. Only 
two patients received vasopressin (antidiuretic hormone) and one received glucagon. In both cases 
these drugs were given late in the resuscitation process and each was preceded by ephedrine, 
metaraminol and adrenaline.  
 
Bradycardia was present in 13.2% of all cases, treated with glycopyrronium in 4.3% and atropine in 
6.2%, a third in association with cardiac arrest. Tachycardia was rare, being treated once with 
amiodarone, which was also used during the management of four cases of cardiac arrest. 
 
IV hydrocortisone was administered in 82.9% of cases (1-4 doses, median dose 200 mg) and 
dexamethasone (administered after the event) in 16.1% of cases (median dose 6mg). Both drugs 
were administered in 8.7% of cases. Two patients received methylprednisolone. Of note 
dexamethasone was also given before the event in 19.2% of cases. Thirty-four patients (12.8%) did 
not receive a steroid, including four fatalities. 
 
IV chlorphenamine was administered in 73.6% (median 10mg, 5-40mg) and IV ranitidine in 5.3% of 
cases. Nine (3%) patients received both drugs (Table 1). We performed further analysis using a 
logistic regression model to elucidate benefit/harm associated with chlorphenamine. Variables 
included; initial resuscitation drugs, (adrenaline bolus, corticosteroids, metaraminol, ephedrine and 
chlorphenamine); patient factors (age group intervals excluding children and over 75 yrs due to 
small numbers) and ASA status (excluding ASA 5 due to small numbers). Outcome was level of harm 
(no harm, low, moderate/severe harm or death) as defined in the accompanying paper.
29
  
Chlorphenamine administration was associated with an increased probability of ‘no harm’ and 
reduced probability of a ‘moderate/severe’ harm: odds ratios 2.20 (1.05-4.58) and 0.41 (0.18-0.91), 
respectively. Chlorphenamine had no effect on the probability of ‘low harm’ or death.  In order to 
exclude chlorphenamine as a surrogate for good (as opposed to ‘poor’ or ‘good and poor’) clinical 
management (noting that chlorphenamine administration was not used as a measure of quality of 
care during panel discussions) we performed a Fischer exact test. This confirmed a significant 
association between administration of chlorphenamine and care being judged as good (P<0.005). 
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Thus, it was not possible to extricate any potential benefits of chlorphenamine from the presumed 
benefits of good care. 
 
(Table 1 near here) 
 
Sugammadex 
Sugammadex was administered during the first six hours following the event in nineteen (7.1%) 
cases (median dose 300mg, range 150 – 1200mg). The suspected trigger agent was rocuronium in 
nine cases, and the actual culprit in seven: Sugammadex did not terminate the reaction in three and 
further vasopressors and bronchodilators were needed. 
 
IV fluids 
IV fluid management was judged inappropriate, almost always as insufficient, in 19% of cases. 
Ninety eight percent patients received IV crystalloids in the first hour after the reaction, 86% during 
the subsequent 2 hours and 69% during the next 2 hours. The median volume administered during 
each time period was 1L (range 0.1L to 6.0L); 1L (range 0.1 to 3.0L) and 0.5L (range 0.1L to 4.5L). The 
only IV colloids administered during the first hour after the anaphylactic event were succinylated 
gelatin products in 25 (9%) cases. 
 
Airway 
Airway management was judged appropriate in 98.8% of cases (Figure 5); in 1.2% of cases it was 
judged that tracheal intubation should have been performed. Airway swelling, airway difficulty and 
complications were uncommon. Tracheal intubation was performed as part of resuscitation in 13.2% 
of patients; in the majority this involved removal of a supraglottic airway and replacement by a 
tracheal tube. In three (1.1%) cases the tracheal tube was removed and replaced as a result of 
suspected oesophageal intubation as part of the differential diagnosis. A front of neck airway was 
instituted in one patient who developed laryngeal oedema and stridor, but other details of this case 
were scarce. In seven patients it was necessary to re-intubate the trachea after completion of the 
primary surgical procedure; in no case was re-intubation difficult due to laryngeal swelling. 
 
Guideline access 
A management guideline was immediately accessible in 86% of cases, mainly as a laminated sheet: 
15% of immediately-available guidelines were contained in designated ‘anaphylaxis-packs’. A 
smartphone was not used to access guidelines in any cases. 
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The AAGBI guideline was most commonly used (60.5% of cases). The RCUK guidelines on 
management of anaphylaxis and on life support were used in 5.3% and 6.4% of cases, respectively 
Local or Trust guidelines accounted for 3.8% of cases. In 44 (18.6%) cases no specific guideline was 
used. The reporting anaesthetist judged that the theatre team contributed effectively to 
management in 87% of cases and was partially-effective in a further 7.7%.  
 
Fatal cases 
Immediate management was prompt in all but one of the ten cases and all resuscitations followed a 
guideline and were managed by a consultant. Resuscitation from cardiac arrest was prompt, 
prolonged and extensive. CPR took place for a median 39 mins and in all cases for >25 minutes. 
Resuscitation included Extra-Corporeal Membrane Oxygenation in one case and immediate cardiac 
catheterization to explore or manage an acute coronary syndrome in two cases. Adrenaline was 
administered IV in all cases including an infusion in five cases. A median of 5 doses (5mg) adrenaline 
was administered (range 2-13mg). No patient received IM or IO adrenaline. Ephedrine, metaraminol, 
glycopyrronium and atropine were used early in resuscitation. Five patients received noradrenaline, 
one vasopressin and one glucagon, administered at 65 minutes after the reaction. Approximately 
half of cases received chlorphenamine and hydrocortisone. Sugammadex was not used. Fluid 
resuscitation volumes were relatively modest 1-4.5L (median 1.5L) in the first hour and in the first 
five hours 1-9.5L, (median 1.5L); only one patient received >4L in total. Five patients did not survive 
initial resuscitation, while five did, of whom one died soon after. Of the four remaining patients, all 
were admitted to ICU and all survived at least one week, but all deaths occurred in <30 days. Four 
patients developed multiple organ failure. 
 
A mast cell tryptase sample was sent in all cases and a dynamic change was identifiable in five cases. 
Mast cell tryptase results are discussed elsewhere.
32
 There were no episodes of recrudescence of 
anaphylaxis. Good elements of care were: appropriately senior resuscitators (10/10); prompt 
recognition of the critical event (9/10); prompt recognition of anaphylaxis (9/10); appropriate airway 
management (10/10) and prompt initiation of cardiac compressions (9/10, 1 uncertain). Inadequate 
fluid administration was a recurrent theme. 
 
Cardiac arrests 
Cardiac arrest was reported in 40 (15%) patients – in 27% of these within 5 minutes of trigger 
administration, though others were preceded by prolonged hypotension. All these patients received 
cardiac compressions; the mean duration was 14 minutes (range 1 to 60 minutes). It was generally 
prolonged in those who died but brief in those who survived: median 8 minutes, IQR 2-8 minutes in 
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survivors. The event was generally promptly recognised and treated. Delay in managing anaphylaxis 
was due to slow diagnosis or uncertain diagnosis (one case each) and loss of IV access (one case). 
Quality of resuscitation is summarized in table 2. On average five doses of IV adrenaline were 
administered (mean 5mg, range 0-12 mg). Half of survivors received an adrenaline infusion after 
initial resuscitation. Second line drugs included noradrenaline to 15 patients, vasopressin to two, 
glucagon to one, intralipid to one and sugammadex to one. Chlorphenamine and steroid were given 
to approximately 75% of patients during resuscitation. Fluid volumes were modest; median volume 
1.75L (range 0-4.5L) during the first hour and 3.25L (range 0-9.5L) during the first 5 hours. Panel 
judgements on quality of care are included in Table 2. 
 
Profound hypotension 
CPR was initiated in 28 (50%) of those with an unrecordable blood pressure, in five (9%) with systolic 
blood pressure <50mmHg and in two (3.8%) with lowest blood pressure of 50-59mmHg. The panel, 
after taking external expert advice, used a threshold of <50mmHg as the point at which CPR was 
indicated in adult patients. Deakin et al.
33
 demonstrated using invasive BP measurement, which 
overestimates systolic blood pressure compared with non-invasive methods,
34
 that systolic blood 
pressure <50mmHg was associated with pulselessness with a 90% positive predictive value. So, 
when the lowest blood pressure was <50mmHg and CPR was not started, this was deemed to be 
suboptimal care. There were 114 (42.9%) such cases. Overall prompt CPR (when the blood pressure 
was <50mmHg or unrecordable) was reported in 23% of cases. Pharmacological treatment was 
judged inadequate in 21% and adrenaline administration was judged inadequate in 17%. Fluid 
administration was deemed inadequate in 24%. Patient characteristics, outcomes and quality of care 
are summarised in Table 2.  
 
(Table 2 near here) 
 
Discontinuation of the trigger agent 
The suspected trigger agent was discontinued in twenty-two of the twenty-six cases where this 
would have been possible. Agents that were not discontinued comprised IV gelatin, a chlorhexidine-
coated central venous line, a second dose of co-amoxiclav and a second dose of protamine. The 
actual trigger agent was not discontinued in four of the fourteen cases where this would have been 
possible, comprising IV gelatin, administration of a second dose of protamine and two instances of 
retained chlorhexidine-coated central venous line. 
 
Continuation of surgery 
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In approximately one third of cases the procedure was unchanged but, in over half the cases, the 
intended surgery was not started. In a small proportion of cases the procedure was modified or 
abandoned. Median severity was Grade 4 in the abandoned cases and Grade 3 in continued cases. In 
two cases cardiopulmonary bypass was used as part of the resuscitation process. 
 
Unplanned hospital stay and critical care admission 
The median unplanned hospital length of stay (LOS) as a result of anaphylaxis was one day, but there 
was a wide range: 18.4% >2 days; 11.7% >3 days; 8.3% >4 days and 6.6% > 5 days. The longest 
unplanned LOS was 150 days. 
 
One hundred and forty-four (54%) patients were transferred to critical care: the majority (70%) for 
level 3 care. The median duration of level 3 care was one day (range 1-9 days), and of level 2 care 
was one day (range 1-25 days). Six patients required level 3 care and five level 2 care for >2 days. No 
patient required an increase in their level of care after admission to critical care. While in Critical 
care, 63% required inotropic support and 5.1% bronchodilator therapy. Of the patients requiring 
inotrope infusions in ICU/HDU, 34.5% received adrenaline, 21.4% both adrenaline and 
noradrenaline, 15.5% noradrenaline, and the remainder other inotropic drugs. 
 
Outcomes (cases of all severity) 
The severity of physical harm (see accompanying paper for definitions)
29
 identified by the review 
panel was none in 8%; low in 51%; moderate in 34%; severe in 4% and uncertain in 3%. Concomitant 
beta-adrenergic blocking drugs were associated with greater severity: 60% of fatalities were taking a 
beta blocker compared with 18% of all cases.  
 
We asked about physical and psychological sequelae after the event. Data was recorded poorly, so 
any estimates must be judged as minima. More complications were recorded in the section of the 
case report form completed before allergy clinical referral (97 sequelae: 69 mild, 21 moderate and 
seven severe) than in that completed after the allergy clinic visit (74 sequelae 41 mild, 27 moderate 
and six severe). Anxiety about future anaesthetics was the most commonly reported consequence, 
accounting for more than half of longer term consequences, in three cases this extended to 
symptoms of post-traumatic stress disorder. Ten patients reported problems with mood, memory or 
co-ordination. There were twelve reports of myocardial infarction, a cerebrovascular event, acute 
kidney injury or new shortness of breath.  
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As a result of anaphylaxis, cancer surgery was delayed in 19 (7.1%) cases, urgent non-cancer surgery 
in eight (3%), non-urgent surgery in 76 (28.6%) and other treatment was delayed in nine (3.4%) 
cases. Total hospital stay was extended as a result of anaphylaxis in 75% of patients (median 1 day, 
range 0-150 days).  
 
Obstetric cases 
We identified eight obstetric cases in NAP6, all of which were Grade 3. The NAP6 Activity Survey 
35
 
estimated 233 886 obstetric anaesthetics are administered per annum in the UK, giving an incidence 
of severe obstetric perioperative anaphylaxis of 3.4 per 100 000. Six patients received neuraxial 
anaesthesia and two general anaesthesia. Six cases occurred in association with anaesthesia for 
caesarean section, most commonly after delivery of the baby. There were no cardiac arrests, 
maternal or neonatal deaths. All patients developed hypotension, in some cases profound. In four of 
six patients who developed severe anaphylaxis during neuraxial anaesthesia, a common feature was 
the patient complaining of feeling unwell before the onset of hypotension or other clinical signs. 
Hypotension commonly developed at a time when spinal-induced hypotension would have been 
anticipated to have settled. 
 
A consultant anaesthetist was involved in the management of all the cases. In five cases there was 
prompt treatment but, in three cases, there was a delay in diagnosis and treatment was delayed. 
Resuscitation drugs differed from those used in non-obstetric cases:  six patients received 
phenylephrine, four adrenaline, and three both drugs. Fluid management was appropriate in all 
cases. An anaphylaxis pack was used to assist management in only two cases. In four cases overall 
care was judged as good and in one good and poor. Identified culprits were chlorhexidine, 
atracurium, suxamethonium and ondansetron and in four cases no trigger was identified. Maternal 
and neonatal outcomes were good in all cases. None of the women who experienced anaphylaxis 
during neuraxial anaesthesia required tracheal intubation. In three women hospital discharge was 
delayed and one patient reported anxiety about future anaesthesia.  
 
Paediatric cases 
Eleven cases of perioperative anaphylaxis in patients <16yrs were reported, three of which were 
emergency procedures. With an estimated 403,000 cases performed per annum, the incidence of 
grade 3-4 anaphylaxis is 2.73 per 100,000 paediatric anaesthetics. Two patients had well-controlled 
asthma. Six cases presented in the operating theatre, three in the anaesthetic room, one during 
transfer from the recovery room to the ward and one in the radiology department. Seven cases 
presented after induction and before surgery. The first clinical feature was bronchospasm and/or 
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high airway pressures in seven (64%) cases with hypotension being the presenting feature in two, 
tachycardia in one and non-urticarial rash in the remaining case. Bronchospasm presented within 
five minutes, whereas hypotension was generally slower in onset. A decrease in end tidal carbon 
dioxide levels was noted in three cases with an absent capnography trace in two of these at some 
point. Two cases exhibited non-laryngeal oedema, which was delayed in one case. There were no 
fatalities in children. The clinical features present at any time during the reaction are shown in Figure 
6. All cases were judged grade 3 by the index anaesthetist: on panel review, six were judged as grade 
4. 
(Figure 6 near here) 
The review panel judged that clinical management was good in four cases, good and poor in two 
cases and was poor in a single case (where adrenaline was not administered). A consultant was 
present during resuscitation in all cases. AAGBI guidelines were used in five, and RCUK guidelines in 
one. In seven cases, there was immediate access to a guideline as a laminated document.  
 
Specific treatment for anaphylaxis was started within five minutes in six of the seven cases where 
bronchospasm and/or high airway pressures were the presenting features. When hypotension or 
tachycardia were the presenting features, specific treatment tended to be started later. Adrenaline 
was administered in ten cases, either IV or IM and an infusion was required in four cases. Other 
vasopressors were used in small numbers of cases. Eight patients received chlorphenamine and 
eight hydrocortisone. Two patients did not receive a corticosteroid. One patient received atropine. 
No patients received phenylephrine, vasopressin, glucagon, glycopyrrolate, sugammadex or 
magnesium sulphate. Ten patients received IV crystalloid, one IV gelatin, and one no IV fluid. The 
volume of IV crystalloid administered during the first five hours is shown in Figure 7.  
 
(Figure 7 near here) 
 
In six cases the procedure was abandoned and four of these were rescheduled, in all cases except 
one judged to be appropriate. Three patients were transferred to HDU/ICU as a result of the event, 
including one to a different hospital. Following resuscitation and clinical recovery, one child was 
reported as being withdrawn and angry and one child reported anxiety about potential further 
anaesthesia. Seven cases were reported through the Trust’s local critical incident reporting system 
but only one case was recorded as being reported to the Medicines and Healthcare products 
Regulatory Authority (MHRA) and two patients were issued with a hazard alert by the anaesthetist. 
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The anaesthetist suspected the causal agent was atracurium in three cases, with single cases of each 
of the following; lidocaine, suxamethonium, piperacillin/tazobactam, teicoplanin, aprotinin, 
cefuroxime, ibuprofen and cryoprecipitate. The review panel identified atracurium in three cases 
and one each of the following; suxamethonium, aprotinin, cefuroxime, ibuprofen and 
cryoprecipitate. The trigger agent could not be confidently-identified in the remaining cases. The 
mechanism of the reaction to ibuprofen was judged to be non-allergic anaphylaxis.  
 
 
(Table 32 near here) 
 
Concordance 
Concordance between triggers suspected by the anaesthetist and identified by the panel is discussed 
in greater detail in a paper exploring investigation of the NAP6 cohort.
32
   
 
Amongst cases with an identified trigger, overall concordance was 75% between the anaesthetist 
and the panel. However, anaesthetists were likely to over-identify NMBAs as triggers and to fail to 
recognise chlorhexidine -induced anaphylaxis. 
 
 
Communication 
The panel judged that there were considerable shortcomings in communication between the 
anaesthetist and the patient following the event. Information given to the patient by the 
anaesthetist about which drugs or other substances they should avoid before attending an allergy 
clinic for investigation was oral in 26.6 %, written in 19.8 %, both in 39.2% and none in 14%. In 222 
cases where this information was available, 29% were issued with a hazard warning card; 39% of 
these by the index anaesthetist.  
 
Discussion. 
Obstetric cases 
Anaphylaxis during pregnancy is very uncommon (≈1.6-3.0 per 100,000 maternities 
36
 
37
 
38
). The 
predominant use of neuraxial techniques likely limits exposure to many of the trigger agents 
associated with general anaesthesia. Previous studies have highlighted latex and suxamethonium as 
culprits 
39
. The incidence during caesarean was reported as 2.1 per 100,000 with antibiotics 
important triggers. Perioperative obstetric anaphylaxis is complicated by the need to ensure the 
safety of both patients and of the potential impact of both maternal hypotension and adrenaline 
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administered to the mother on uteroplacental haemodynamics. The literature is generally reassuring 
with good maternal and neonatal outcomes, but it is notable that maternal outcomes may be less 
good when anaphylaxis occurs during caesarean delivery and neonatal outcomes worse when 
maternal anaphylaxis develops during labour. The placenta is metabolically active and metabolises 
histamine and other endogenous mediators,
40
 potentially protecting the fetus from mediator-
related morbidity.  
 
The overlapping clinical features of anaphylaxis with other acute obstetric morbidities can hinder the 
diagnosis of anaphylaxis, particularly during the onset or in the presence of neuraxial block. In the 
absence of vasopressor-prophylaxis, hypotension occurs in two thirds of patients during spinal 
anaesthesia. However other conditions such as aortacaval compression, haemorrhage, and much 
more rarely, amniotic fluid or thromboembolic embolus can lead to severe hypotension.   
 
Phenylephrine was the most commonly-used vasopressor. Phenylephrine infusions are 
recommended to prevent and treat hypotension associated with spinal anaesthesia
41
 and are 
therefore immediately available and familiar to the anaesthetist working on labour ward. In the 
presence of spinal anaesthesia, hypotension from other causes can be exacerbated and require large 
doses of vasopressor to treat effectively. Adrenaline is recommended for the management of 
anaphylaxis and although there might be theoretical concerns about its potential effect on the 
uteroplacental circulation, particularly when used to treat anaphylaxis before delivery, this effect is 
short lived
42
 and any transient effect on uteroplacental circulation is likely to be less than the impact 
of maternal hypotension. Thus, adrenaline should be first-line treatment in obstetric patients. 
 
Paediatric cases 
Perioperative anaphylaxis is uncommon in children and reported incidences vary considerably.
43
 
44
 
45
 
Latex and NMBAs have historically been prominent triggers and antibiotics less commonly cited. This 
likely is influenced by differences in both procedures commonly undergone by children and by 
anaesthetic technique.  
 
The low incidence of paediatric perioperative anaphylaxis may have several causes. Latex exposure 
has reduced significantly in recent years. It is also likely that children are both less sensitised and less 
exposed than adults to allergens during the perioperative period. NAP6 indicates that NMBAs and 
antibiotics were used in 24.7% and 26.4% of paediatric general anaesthetics, compared to 47% and 
57% in adults  
35
  The Allergen survey also
35
showed that 14% of children received only sevoflurane 
for induction and maintenance; a low anaphylaxis-risk anaesthetic. 
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Unlike in adult patients, bronchospasm and or high airway pressures was the most common 
presenting feature in children. Bradycardia was also more common in children compared with adults 
(18% vs 12.6%). Cardiopulmonary resuscitation was not performed in any paediatric case: four 
children’s systolic blood pressure was <50mmHg, but expert opinion did not favour setting a blood 
pressure below which CPR should be initiated in children.  
 
Given the small number of cases reported in children, it is not possible to make confident 
conclusions concerning risk rates with different dugs. However, the number of cases of atracurium 
and suxamethonium appear to be proportionate to the number of exposures. Atracurium was the 
most-used NMBA in children (57%) by a large margin, followed by rocuronium (5.2%) and 
suxamethonium (2.6%). Paediatric cases are increasingly intubated without an NMBA.
46
  
 
There were no cases of latex-induced anaphylaxis which may reflect its declining presence in the 
workplace
47
 as well as an increased awareness as a potential hazard following historical paediatric 
case reports.
48
.  
 
Immediate management: all cases 
It is reassuring that resuscitation involved a consultant or other career grade anaesthetist in all 
cases. The majority (88.7%) of UK patients are anaesthetised by consultant or career grade 
anaesthetists:
49
 nevertheless, trainees were willing to call for help and the theatre team contributed 
effectively to management in almost 90% of cases. Recognition of perioperative anaphylaxis may be 
difficult but nevertheless was prompt in 83% of cases.  
 
Overall quality of management was judged 'good' in slightly less than half of the cases. The deficits 
were multi-factorial and included insufficient IV fluids (19% of cases), non-administration (17.7%) or 
late administration of adrenaline, delays in recognising anaphylaxis and starting specific treatment, 
and lack of cardiac compressions where the BP was <50mm Hg or unrecordable. An apparent 
reluctance to give adrenaline has been previously reported.
50
 We suggest four factors operate. First, 
anaphylaxis is very uncommon: an anaesthetist will see perioperative anaphylaxis on average only 
once every 7.25 years.
51
 Second, when faced with hypotension, it has been the anaesthetist's 
previous experience that repeated doses of the ‘usual’ vasopressors will eventually restore the blood 
pressure, encouraging a 'more of the same' approach. An analogous behaviour is the 'task fixation' 
sometimes observed when managing a difficult intubation. Third is the phenomenon of crisis-denial 
and the realisation that giving adrenaline will affirm that a crisis exists. Fourth, unless the 
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anaesthetist has a critical care background, administration of adrenaline may be outside their 
previous experience. It is also possible that the anaesthetist may have, unfounded, concerns that 
adrenaline is contra-indicated in patients with coronary artery disease or in obstetric patients. In 
addition to immediate availability of management guidelines, overcoming these barriers to 
adrenaline administration requires frequent practice drills and, ideally, simulator training.
52
 
Reluctance to administer large volumes of IV fluids was also observed, particularly in patients with 
cardiac disease, perhaps through misplaced fears of causing fluid overload and precipitating heart 
failure. 
Vasopressin is recommended for intractable hypotension in several guidelines
5 10
 but was 
administered in only two cases despite the presence of persistent hypotension, evidenced by the 
administration of noradrenaline infusion in almost 1 in 5 cases. Several cardiac arrests were 
preceded by prolonged hypotension. Of note, earlier guidelines omitted this drug
3
  and it likely that 
awareness is limited. It is also likely that vasopressin is unavailable in many anaesthetising sites, a 
situation addressed by our recommendations. Similar comments apply to glucagon.  
 
We sought to be in a position to make firm recommendations about the administration of 
chlorphenamine. Using level of harm as the outcome and including all putative factors, logistic 
regression identified chlorphenamine administration was associated with increased probability of 
'no harm' and reduced probability of ‘moderate/severe’ harm. However, the confidence intervals 
were wide and a Fischer exact test demonstrated that anaesthetists who gave overall good care as 
determined by the review panel were more likely to have administered chlorphenamine, 
presumably as a result of following UK guidelines, i.e. we were unable to demonstrate causality. The 
review panel considered that chlorphenamine should continue to be recommended, though mainly 
to reduce angioedema/urticaria. 
 
Our data do not support efficacy of sugammadex in rocuronium-induced anaphylaxis. Of seven 
proven cases, in four no further pharmacological treatment was needed after sugammadex was 
given, but three required further vasopressor and or bronchodilator therapy.  
 
Patients with profound hypotension had less good quality of care than any other patient group. They 
were more likely to have delayed diagnosis and administration of adrenaline, and CPR was a rarity: 
significant numbers of patients came to harm. Early recognition of these patients as at high risk of 
harm, early management with adrenaline, fluids and CPR provides an opportunity to improve 
outcomes.  
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Treatment and referral to allergy clinics might be improved by provision of specific Anaesthetic 
anaphylaxis treatment packs and Anaesthetic anaphylaxis investigation packs. These are described in 
Supplementary materials A and B respectively.   
 
The majority of patients in our cohort required transfer to critical care, mostly for level 3 care and 
half of patients required catecholamine infusions and a substantial number of patients were harmed 
by their anaphylactic event. While the decision to abandon or continue surgery needs to be a 
balanced one based on individual circumstances, the review panel were of the view that it is 
inadvisable for surgery to proceed after life-threatening anaphylaxis (grades 3 and 4) unless there 
are over-riding reasons to do so.  Sadleir
53
 demonstrated that patients with Grade 3 anaphylaxis who 
continued with surgery (42.2%) did not require more intra-operative adrenaline or longer 
postoperative ventilation than those in whom the procedure was abandoned. However, surgery was 
more likely to be abandoned in the more severe Grade 3 cases. The authors attempted to control for 
this effect by using the degree of mast cell tryptase rise as a surrogate for severity but NAP6 data 
demonstrated no relationship between acute mast cell tryptase levels and indices of clinical 
severity.
54
 In Sadleir's study, surgery was continued in a small proportion of cases of grade 4 
anaphylaxis. 
 
The potential risks of patients undergoing surgery without adequate precautions before they have 
attended an allergy clinic are underlined by a case in which an NMBA was the suspected culprit but 
chlorhexidine was demonstrated to be the cause on allergy testing. In most circumstances urgent 
surgery can be performed before allergy clinic assessment by applying some simple, cautious rules: 
we have developed a management plan (Appendix 1) for patients in whom surgery is needed before 
a clinic diagnosis has been obtained. 
 
Gibbison et al demonstrated that perioperative anaphylaxis accounts for a third of all cases of 
anaphylaxis admitted to critical care units;
55
 a similar proportion to that admitted from the 
emergency department following community anaphylaxis. Our data, 144 admissions over a one year 
period, are compatible with Gibbison's. Almost two thirds of patients admitted to ICU/HDU required 
continuing inotropic support, but only 5% needed continuing bronchodilator therapy; we believe this 
is a novel finding. Of note, there were no cases of so-called biphasic anaphylaxis. 
 
The mortality rate (3.8%) observed in NAP6 corresponds with other large series. A significant finding 
was the association with increased age, increased ASA, morbid obesity, coronary artery disease and 
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beta blocker and ACEI medication. These factors are likely to interact and may not each be 
independent predictors of poor outcome but are worthy of further research.  
 
We are not aware of other studies which investigated a wide range of physical and psychological 
adverse sequelae. Severe anxiety and mood changes, mild/moderate memory impairment and 
impaired mobility were observed. Physical harm was uncommon but did include one front of neck 
airway and a small number of patients who experienced myocardial infarction, stroke, acute kidney 
injury or new shortness of breath as a consequence of perioperative anaphylaxis or during their 
recovery. It is likely these sequelae are underdiagnosed. We recommend that all patients should be 
followed-up after perioperative anaphylaxis.  
 
In order to facilitate this and the many other tasks that are needed for a department of anaesthesia 
to be ‘institutionally prepared’ to manage perioperative anaphylaxis we recommend that all 
departments of anaesthesia should have a 'Departmental Lead for Anaphylaxis’. The suggested roles 
and responsibilities are set out in Supplementary materials C.   
 
In appendix 2 we list a series of recommendations intended to improve care. They are numerous and 
some simply reinforce known good practice. However, each recommendation is founded on the 
direct and indirect findings of NAP6. We hope that (as with previous NAPs
56 57
) the many 
recommendations we have made will be largely implemented. Others may stimulate discussion or 
provide hypotheses for future research. We hope this will both increase awareness of the topic and 
improve institutional and individual preparedness for these infrequent but potentially life-
threatening events. This will have the potential to make inroads into avoiding avoidable anaphylaxis, 
improving the quality of care patients receive when it occurs and afterwards, both by anaesthetists 
and in allergy clinics.  
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Appendix 1: Urgent surgical intervention after suspected perioperative anaphylaxis and 
prior to allergy investigations: NAP6 suggested management plan 
 
It is possible to provide safe anaesthesia in almost every case and unnecessary to postpone urgent 
surgery. 
 
 It is important to discuss the case with a consultant Allergist or Clinical Immunologist as soon as 
possible after the suspected anaphylactic event 
 Regional anaesthesia, where practical, may be a sensible option to enable avoidance of most 
drugs suspected to have caused anaphylaxis during previous general anaesthesia 
 If anaesthesia was induced with propofol and general anaesthesia is required, the choice of 
induction agents includes inhalational agents, thiopental, etomidate (non-lipid formulation) and 
ketamine.  
 If tracheal intubation is required and an NMBA is contra-indicated: 
o A remifentanil infusion, magnesium sulphate and topical anaesthesia are helpful 
adjuncts to deep anaesthesia in facilitating laryngoscopy and intubation 
o Where remifentanil was used in the previous anaesthetic, consider the use of alfentanil  
o Awake intubation under topical anaesthesia is an alternative 
 If local anaesthetics are not contra-indicated, sufficient surgical muscle relaxation can usually be 
provided if necessary with an adequate depth of anaesthesia and adjunct neuraxial block, 
transversus abdominis blocks, rectus sheath blocks or other peripheral nerve block 
 Pre-warn the theatre team beforehand, and be prepared to diagnose and treat anaphylaxis 
promptly. Consult appropriate guidelines in advance 
 Premedication with antihistamines and steroids may reduce the severity of reactions caused by 
non-specific histamine release but will not prevent anaphylaxis. 
 
Avoid the following if administered/exposed during the 60 minutes prior to the suspected 
anaphylactic event: 
 
 All drugs to which the patient was exposed, with the exception of inhalational anaesthetic 
agents 
 All antibiotics of the same class that was administered (beta lactams; macrolides; 
fluoroquinolones; aminoglycosides; monobactams; carbapenems). The surgical and anaesthetic 
team should discuss antibiotic choice with a microbiologist 
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 If an NMBA was administered during this period, all NMBAs should be avoided unless it is 
absolutely impossible to do so, due to the risk of cross-sensitivity 
 Chlorhexidine (including chlorhexidine antiseptic wipes, medical gel (e.g. used before catheter 
insertion) and chlorhexidine-coated intravascular lines/catheters) 
 IV colloids  
 Radiological contrast and dyes used for lymph node identification 
 Latex 
 Local anaesthetics of the same class (amides; esters) 
 Histamine-releasing drugs (morphine and codeine) as the previous reaction may have been due 
to non-specific histamine-release 
If past anaesthetic records are not available, in addition to the above: 
 
 Assume that the patient previously received an antibiotic. Antibiotics are the most common 
cause of perioperative anaphylaxis in the UK. Discuss antibiotic prophylaxis with a microbiologist 
beforehand 
 Assume that the patient was previously exposed to propofol, morphine, chlorhexidine, latex, IV 
colloid, and an NMBA 
 If possible, use local or regional anaesthesia in patients who have had a previous suspected 
anaphylactic event during general anaesthesia, and vice versa 
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Appendix 2. NAP6 Recommendations for anaesthetists 
 
Recommendations regarding allergy clinic investigations can be found in the accompanying paper 
(Bill CEA) and all recommendations including those for research are in the main report at 
http://www.nationalauditprojects.org.uk/NAP6Report#pt . 
 
DEPARTMENTAL ORGANISATION & IMMEDIATE MANAGEMENT  
National 
1. Relevant standard setting and examining organisations should ensure that the detection, 
management and referral for investigation of perioperative anaphylaxis is a core curriculum 
content for anaesthetists and intensivists.  
2. Allergy history-taking should be included in core curricula for medical and nursing training. 
Nurses in pre-operative assessment clinics require particular skills and training. 
 
Institutional 
3. Procedures should be in place to ensure that an appropriate patient allergy history is sought and 
recorded before anaesthesia is administered. 
4. There should be a departmental lead for perioperative anaphylaxis in each department of 
anaesthesia. This role should be supported by appropriate time and DCC/SPA allocation. 
5. Department leads and their local allergy clinic should liaise directly to ensure current phone 
numbers and email contacts for the clinic are readily available to anaesthetists in their 
department, and kept up to date. 
6. Departments of anaesthesia should have protocols for the detection, management and referral 
for investigation of perioperative anaphylaxis. These should be readily accessible to all 
departmental members, widely disseminated and kept up to date.  
7. Clinical Directors of anaesthetic departments should ensure their anaesthetists have been 
trained in the management of perioperative anaphylaxis. 
8. Perioperative anaphylaxis guidelines and/or a management algorithm should be immediately 
available wherever anaesthesia is administered. 
9. Anaesthesia anaphylaxis treatment packs, including an anaphylaxis management algorithm, 
adrenaline pre-filled syringes suitable for IV administration, hydrocortisone and details of the 
location of glucagon and vasopressin should be immediately available wherever anaesthesia is 
administered. 
10. Anaesthesia anaphylaxis investigation packs, including tryptase sampling tubes and paperwork 
that describes (a) details of blood tests required and their timing (b) instructions on referral for 
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further investigation and allergy clinic details (c) documentation for the patient, should be 
available in all theatre suites. 
11. Vasopressin and glucagon for the management of intractable perioperative anaphylaxis should 
be available within 10 minutes, wherever anaesthesia is administered.  
12. Referrals to allergy clinics for investigation of perioperative anaphylaxis should include full 
details of the patient’s medication, the event and timings of all drugs administered prior to the 
event. A standardised form (e.g. the AAGBI proforma) should accompany the referral. 
13. Investigation of perioperative anaphylaxis should include follow-up, either in hospital or in 
primary care, to detect adverse sequelae such as new anxiety, impairment of cognition or 
activities of daily living or deterioration in cardiorespiratory or renal function. The anaesthetic 
department lead should co-ordinate this. 
 
Individual 
14. All anaesthetists responsible for perioperative care should be trained in recognition and 
management of perioperative anaphylaxis and relevant local arrangements. 
15. Adrenaline is the primary treatment of anaphylaxis and should be administered immediately 
anaphylaxis is suspected. In the periop rative setting this will usually be IV. 
16. Where a critical perioperative hypotensive event occurs, and perioperative anaphylaxis is one of 
several differential diagnoses, treatment for anaphylaxis should start promptly as there is little 
to be lost and much to be gained.  
17. If IV access is not immediately available intramuscular or interosseous routes should be used 
promptly, until IV access is established.   
18. A rapid IV crystalloid (not colloid) fluid challenge of 20ml/kg should be given immediately. This 
should be repeated several times if necessary. 
19. During anaphylaxis with a systolic blood pressure <50mmHg in adults, even without cardiac 
arrest, CPR should be started simultaneously with immediate treatment with adrenaline and 
liberal IV fluid administration.  
20. If an IV colloid is being administered at the time of the anaphylactic event, it should be 
discontinued, and the IV administration set replaced. 
21. Administration of IV vasopressin 2 Units, repeated as necessary, should be considered when 
hypotension due to perioperative anaphylaxis is refractory 
22. During perioperative anaphylaxis in patients taking beta blockers early administration of IV 
glucagon 1 mg should be considered, repeated as necessary. 
23. When anaphylaxis occurs following recent insertion of a chlorhexidine-coated central venous 
catheter, this should be removed and, if appropriate, replaced with a plain one. 
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24. A corticosteroid should be administered as part of resuscitation of perioperative anaphylaxis.  
25. Chlorphenamine may be given as part of the resuscitation process, but NAP6 found no evidence 
of either benefit or harm. It may reduce angioedema and urticaria. 
26. Blood samples for mast cell tryptase (MCT) should be taken in accordance with national 
guidelines.  
a. 1
st
 sample as soon as the patient is stable.  
b. 2
nd
 sample as close to 1 -2 hours as possible after the event.  
c. 3
rd
 (baseline) at least 24 hours after the event 
27. All patients experiencing suspected perioperative anaphylaxis should be referred for specialist 
investigation in an allergy clinic. This is the responsibility of the consultant anaesthetist in charge 
of the patient at the time of the event: i.e. the consultant anaesthetising or supervising the case. 
28. Where a trainee refers a patient to an allergy clinic the contact details of a consultant 
anaesthetist should be included in the referral. 
29. If there is a need for urgent referral, the anaesthetist should phone the allergy clinic for advice, 
as well as making a written referral.  
30. Where perioperative anaphylaxis has led to deferment of urgent surgery, alternative 
anaesthesia should be feasible by following simple rules. 
Research 
31. There remains uncertainty about the benefits or potential harm of administering antihistamine 
drugs during resuscitation of perioperative anaphylaxis. Clinical trials would provide valuable 
evidence. 
32. There remains uncertainty about the benefits or potential harm of administering sugammadex 
during resuscitation of perioperative anaphylaxis and for management of rocuronium induced 
anaphylaxis specifically. Clinical trials would provide valuable evidence. 
 
PATIENT EXPERIENCE 
Institutional 
33. Consent should always be informed. Therefore, patients should be informed of the risk of 
anaphylaxis pre-operatively. Patient information leaflets may be suitable as part of this process.  
34. Following a peri-operative anaphylactic event and before discharge from hospital the patient 
should be provided with a letter from their anaesthetist. This letter should be in addition to the 
discharge summary and a copy should be sent directly to the patient’s GP. 
 
Research 
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35. The effect of a perioperative anaphylactic event on a patient’s physical and physiological well-
being in both the medium and the long term in not well understood. Research into this topic and 
dissemination of the outcomes could be of great benefit to patients.  
 
 
CLINICAL FEATURES 
Institutional 
36. All anaesthetists responsible for perioperative care should be trained in recognition and 
management of perioperative anaphylaxis and relevant local arrangements.  
Individual 
37. Perioperative anaphylaxis can present with a single clinical feature, in particular isolated 
hypotension. Anaesthetists should exercise a high index of suspicion in recognising perioperative 
anaphylaxis and commence treatment promptly.  
38. In patients with asthma, the occurrence of bronchospasm or high airway pressures should not 
automatically be attributed to acute asthma as, in these patients this is frequently the 
presenting feature of life-threatening anaphylaxis.  
39. As anaphylaxis may be delayed, particularly with some oral drugs, referrals to allergy clinics 
should include details of all agents that the patient has been exposed to within at least the 
previous 120 minutes  
40. During perioperative anaphylaxis in patients taking beta blockers early administration of IV 
glucagon 1mg should be considered, repeated as necessary.  
 
Research 
41. Further studies are required to clarify the role of a fall in end-tidal CO2 concentration in the 
early recognition and management of severe perioperative anaphylactic reactions.  
42. The role of glucagon and vasopressin in refractory anaphylaxis (particularly in high risk groups 
such as the elderly, and those taking beta blockers or ACE inhibitors) needs further investigation. 
43. Studies are indicated to establish the influence of mast cell activation disorders on the severity 
and clinical presentation of perioperative anaphylaxis.  
44. Research would be of value to investigate the effect of corticosteroids, both given prior to 
anaphylaxis and for its treatment.  
 
DEATHS, CARDIAC ARREST and PROFOUND HYPOTENSION 
Severe perioperative anaphylaxis here refers to perioperative anaphylaxis requiring CPR or 
with profound hypotension (e.g. systolic blood pressure <50mmHg). 
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45. In patients who experience perioperative anaphylaxis with a high risk of adverse outcome 
(elderly, obese, ASA≥3, patients taking beta blockers or ACEI, prolonged CPR), anaesthetists 
should be prepared to escalate treatment early.  
46. During anaphylaxis with a systolic blood pressure <50mmHg in adults, even without cardiac 
arrest, CPR should be started simultaneously with immediate treatment with adrenaline and 
liberal IV fluid administration. 
47. During perioperative anaphylaxis in patients taking beta blockers early administration of IV 
glucagon 1mg should be considered, repeated as necessary.  
48. Administration of IV vasopressin 2 Units, repeated as necessary, should be considered when 
hypotension due to perioperative anaphylaxis is refractory. 
49. The need for a vasopressor infusion should be anticipated after severe perioperative 
anaphylaxis.  
50. Non-essential surgery should not be started after severe perioperative anaphylaxis.  
51. Where severe perioperative anaphylaxis occurs during non-essential surgery the operation 
should be curtailed unless there is an overriding reason to continue. 
52. Patients with severe anaphylaxis should be admitted to critical care (HDU/ICU). 
53. While it is not possible to be definitive about how long a patient should be observed after Grade 
3-4 perioperative anaphylaxis, it would seem imprudent for them to be discharged on the same 
day as the event. 
54. All cases of severe perioperative anaphylaxis, including fatalities, should be discussed with an 
allergy clinic at the first available opportunity. 
 
REPORTING  
Institutional 
55. MHRA should improve communication with clinicians; for example, providing an annual report 
which includes perioperative anaphylaxis 
 
National 
56. The departmental lead should ensure all cases have been reported to the Trust incident 
reporting system.  
57. The departmental lead should ensure all cases are reported (by the anaesthetist encountering 
the reaction, or the departmental lead) to the MHRA as soon as possible after the event and 
record the MHRA case identifier for future reference.  
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58. The department lead should (using the MHRA case identifier) ensure the MHRA record is 
updated after allergy clinic investigation is completed, to ensure the information held is 
accurate. 
 
Individual 
59. The departmental lead should be informed of the case. 
60. The MHRA case identifier should be included in the referral to the allergy clinic. 
61. All cases of grade 3-5 perioperative anaphylaxis should be presented and discussed at local 
morbidity & mortality meetings, for purposes of education and familiarisation. 
 
NMBA 
Individual 
62. Except in cases of known or suspected allergy to specific NMBAs, the risk of anaphylaxis should 
not be an over-riding factor in choice of NMBA, as this varies little between NMBAs.  
 
Research 
63. Further research on population sensitisation by pholcodine is needed. If a causal association is 
confirmed, withdrawal of pholcodine-containing medicines from the UK market should be 
formally considered. 
64. There remains uncertainty about the benefits or potential harm of administering sugammadex 
during resuscitation of perioperative anaphylaxis and for management of rocuronium-induced 
anaphylaxis specifically. Clinical trials would provide valuable evidence. 
 
ANTIBIOTICS 
Institutional 
65. Patients with reported allergy to a beta-lactam antibiotic and at least one other class of 
antibiotics should be referred for specialist allergy investigation, before elective surgery, in line 
with NICE CG183: Drug allergy: diagnosis and management. 
66. If antibiotic allergy is suspected despite negative skin tests, challenge testing should be 
performed. 
67. Trust guidelines on antibiotic prophylaxis for surgery should be immediately available to 
anaesthetic and surgical teams in theatre. 
 
Individual 
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68. Antibiotic administration should strictly follow national or local guidelines. 
69. A test dose of antibiotic should not be used, as it will not prevent or reduce the severity of 
anaphylaxis. 
70. Ninety per cent of anaphylaxis due to antibiotics presents within ten minutes of administration. 
When perioperative antibiotics are indicated they should be administered as early as possible, 
where practical at least 5-10 minutes before induction of anaesthesia, providing this does not 
interfere with their efficacy. 
71. The anaesthetist should consider co- amoxiclav or teicoplanin amongst the likely culprits when 
anaphylaxis occurs after their administration. 
72. Broad beta lactam avoidance advice should be discouraged, and patients should be further 
investigated to clarify the drug(s) to avoid and to identify safe alternatives.  
 
CHLORHEXIDINE 
National 
73. The MHRA should work with manufacturers of medical devices, e.g. central venous (and other 
intravascular) catheters to ensure that products are labelled clearly and prominently, to identify 
whether they contain chlorhexidine or not. 
 
Institutional 
74. Operating theatres should have an accessible list of chlorhexidine-containing items. Appropriate 
alternatives should be available for patients with suspected or confirmed chlorhexidine allergy. 
75. Investigation of suspected perioperative anaphylaxis should include chlorhexidine. 
 
Individual 
76. Chlorhexidine allergy should be included in the allergy history taken by anaesthetists, nurses and 
other healthcare professionals.  
77. Clinical teams should be aware of ‘hidden chlorhexidine’ such as in urethral gels and coated 
central venous catheters and should consider this as a potential culprit if perioperative 
anaphylaxis occurs. 
78. When anaphylaxis occurs following recent insertion of a chlorhexidine-coated central venous 
catheter, this should be removed and, if appropriate, replaced with a plain one.  
 
PATENT BLUE DYE 
Individual  
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79. If administration of Patent Blue dye is planned during surgery, the surgical team should discuss 
the risk of anaphylaxis as part of the consent process for surgery. 
80. If anaphylaxis occurs in a patient who has received Patent Blue dye, it should not be assumed 
that this is the culprit, and the patient should be referred for specialist allergy investigation. 
81. Where pulse oximeter saturations fall during anaphylaxis in a patient who has received Patent 
Blue dye, hypoxia should be assumed to be real. A blood gas sample should be taken, when the 
patient is stable enough for this. 
 
INVESTIGATION 
82. Specialist perioperative allergy clinics should adopt an MDT approach, including where practical 
having an anaesthetist with a special interest in the allergy clinic. Where this is not practical 
cases should be discussed with an anaesthetist before the patient attends the clinic. 
83. Referrals to allergy clinics for investigation of perioperative anaphylaxis should include full 
details of the event and a full list of the patient’s medication and drugs administered prior to the 
event. A standardised form (e.g. the AAGBI proforma) should accompany the referral.  
Individual 
84. All patients experiencing suspected perioperative anaphylaxis should be referred for specialist 
investigation in an allergy clinic. This is the responsibility of the consultant anaesthetist in charge 
of the patient at the time of the event: i.e. the consultant anaesthetising or supervising the case.  
85. The anaesthetist referring the patient for investigation of perioperative anaphylaxis should 
explain the importance of attending and allay any fears to improve uptake of allergy clinic 
appointments. 
 
OBSTETRIC 
Institutional  
86. Obstetric units should ensure immediate availability of anaesthetic anaphylaxis treatment and 
investigation packs wherever general or regional anaesthesia is administered 
 
Individual 
87. An allergy history should be taken even when there is extreme urgency to deliver the baby. 
88. Anaesthetists should be vigilant to non-obstetric causes of hypotension in obstetric patients. 
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89. Anaphylaxis in obstetric patients should be managed following the same principles as in non-
obstetric patients. Adrenaline should not be withheld for fear of a detrimental effect on 
placental perfusion. 
90. Anaphylaxis should be actively considered where the cause of maternal hypotension or collapse 
is unclear, and mast cell tryptase levels should be measured. 
91. Anaesthetists should be aware that hypotension due to anaphylaxis can be exacerbated by 
neuraxial blockade and or aortocaval compression.  
 
PAEDIATRIC  
Institutional 
92. Protocols and anaesthetic anaphylaxis treatment and investigation packs appropriate for 
children should be immediately available wherever paediatric anaesthesia is 
administered 
93. All anaesthetists administering anaesthesia to children should be trained in the 
management of paediatric anaphylaxis. 
94. The preparation of drugs for management of paediatric anaphylaxis may be prone to 
error in the emergency setting. Paediatric anaesthetists should consider rehearsal of 
drills locally or in a simulation setting.  
 
CRITICAL CARE 
95. Patients with severe anaphylaxis should be admitted to critical care (HDU/ICU). 
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Table 1 ASA grade, level of care and outcomes in patients receiving chlorphenamine or no 
chlorphenamine for grade 3-5 perioperative anaphylaxis. 
 
 CHLORPHENAMINE 
n = 195 
NO CHLORPHENAMINE 
n = 65 
. 52.3% 
45.1% 
3% 
46.2% 
46.2% 
8% 
Prompt cardiac compressions  46%  50%  
Level 2 care 11% 11% 
Level 3 care 33.8% 13.9% 
Inotropes needed in ICU   31.8% 12.3% 
Physical harm: None  3.6% 12.3% 
Physical harm: Low  39% 24.6% 
Physical harm: Moderate  26.2% 16.9% 
Physical harm: Severe  2.6% 7.7% 
 
Table 2. Quality of resuscitation and outcomes in patients who died, compared to those who 
survived cardiac arrest, or experienced profound hypotension or did not experience profound 
hypotension.  
 
 Deaths 
 (n=10) 
Non-fatal 
cardiac arrest 
(n=31) 
BP <50 but not 
cardiac arrest or 
death 
(n=79) 
All others 
(n=135) 
 
Quality of resuscitation 
 
Appropriate resuscitator 100% 100% 100% 98% 
Prompt recognition 100% 91% 98% 99% 
Prompt diagnosis of 
anaphylaxis 
88% 82% 80% 85% 
Prompt treatment of 
anaphylaxis 
70% 83% 65% 78% 
Adrenaline administered as 
needed 
90% 100% 76% 77% 
 
Prompt CPR when indicated 90% 91% 2% 67% 
 
Appropriate fluid 67% 81% 78% 83% 
 
Good initial management 60% 65% 8% 58% 
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Poor initial management 
 
0% 9% 34% 8% 
Outcomes 
Outcomes where known 
(median) 
 
Severe Moderate Moderate 
 
Low 
% experiencing any harm 100% 74% 59% 60% 
ICU for vasopressors 
(% of all cases) 
 
n/a 67% 32% 23% 
Time on ICU 
(median, all cases) 
 
n/a 2 0 1 
Unplanned hospital length of 
stay 
 
n/a 2 1 
 
1 
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Figure 1. Pathophysiological mechanisms responsible for anaphylactic shock 
 
 
 
Figure 2 Quality of management of perioperative anaphylaxis by anaesthetists (% of cases) 
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Figure 3 Elapsed time (minutes) between drug administration (suspected trigger agent) and 
recognition of a critical incident and suspecting anaphylaxis. Blue – Time to recognise critical 
incident, orange, time to suspect anaphylaxis. 
 
 
 
Figure 4. Speed of starting anaphylaxis-specific treatment after first clinical feature (% of cases). 
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Figure 5. Vasoactive drugs administered during initial management of perioperative anaphylaxis 
(% of cases). 
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Figure 6. Number of children exhibiting clinical features at any time during the anaphylactic 
episode. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Volume of IV crystalloid (ml/kg) administered to children during the first five hours after 
an anaphylactic event (median, range). 
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